Translational Neuroimmunology, Volume 8

Professor Nima Rezaei gained his medical degree (MD) from Tehran University of Medical Sciences and subsequently obtained an MSc in Molecular and Genetic Medicine and a PhD in Clinical Immunology and Human Genetics from the University of Sheffield, UK. He also spent a short-term fellowship of Pediatric Clinical Immunology and Bone Marrow Transplantation in the Newcastle General Hospital. Professor Rezaei is now the Full Professor of Immunology and Vice Dean of Research, School of Medicine, Tehran University of Medical Sciences, and the co-founder and Head of the Research Center for Immunodeficiencies. He is also the founding President of the Universal Scientific Education and Research Network (USERN). Professor Rezaei has already been the Director of more than 55 research projects and has designed and participated in several international collaborative projects. Professor Rezaei is an editorial assistant or board member for more than 30 international journals. He has edited more than 35 international books, has presented more than 500 lectures/posters in congresses/meetings, and has published more than 1,000 scientific papers in the international journals.

1. Introduction on the Neuroimmunology of Multiple Sclerosis 2. Immunopathology of multiple sclerosis 3. Biomarkers of multiple sclerosis 4. Translational research into the pathogenesis of secondary progressive multiple sclerosis 5. Neuroimmunology of fatigue in multiple sclerosis 6. Microbiome and multiple sclerosis 7. Interaction with parasites and herpesviruses in people with multiple sclerosis - potential applications for prevention and treatment 8. Cytotoxic cells in multiple sclerosis: new targets for treatment 9. Targeting leukocytes in multiple sclerosis: therapeutic perspectives 10. Antibodies and antibody fragments developed for treatment of multiple sclerosis 11. Sphingosine-1-Phosphate, its Receptors, and their Role in Multiple Sclerosis, an Inflammatory and Autoimmune Disease of the Central Nervous Systems 12. Innate and adaptive immunomodulation by burton tyrosine kinase (BTK) inhibitors: review of emerging multiple sclerosis treatment